Group One Trading
FDMT icon

Group One Trading’s 4D Molecular Therapeutics FDMT Stock Holding History

Group One Trading’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,998
Closed -$19.5K – 7861
2026
Q1 		$18.6K Buy
+1,998
New +$17.4K ﹤0.01% 6011
2025
Q1 		– Sell
-3,711
Closed -$17.5K – 7824
2024
Q4 		$20.7K Buy
+3,711
New +$29.1K ﹤0.01% 5661
2024
Q3 		– Sell
-2,065
Closed -$34.3K – 6825
2024
Q2 		$43.3K Buy
+2,065
New +$51.8K ﹤0.01% 4620
2024
Q1 		– Sell
-3,691
Closed -$94.2K – 7297
2023
Q4 		$74.8K Buy
3,691
+3,266
+768% +$43K ﹤0.01% 4717
2023
Q3 		$5.41K Sell
425
-616
-59% -$10.3K ﹤0.01% 6662
2023
Q2 		$18.8K Buy
1,041
+250
+32% +$4.6K ﹤0.01% 6027
2023
Q1 		$13.6K Buy
+791
New +$15.4K ﹤0.01% 5766
2022
Q1 		– Sell
-242
Closed -$5K – 8220
2021
Q4 		$5K Buy
+242
New +$5.93K ﹤0.01% 7629

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Group One Trading's FDMT Position: Q2 2026 in Review

Group One Trading sold out of 4D Molecular Therapeutics (FDMT) in Q2 2026, closing a stake of 1,998 shares — an estimated $19.5K sold.

Group One Trading first reported a position in FDMT in Q4 2021 and held it in 8 quarters. The position peaked at $74.8K in Q4 2023. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Group One Trading reported no remaining 4D Molecular Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Group One Trading sold 1,998 4D Molecular Therapeutics shares in Q2 2026, an estimated $19.5K.
  • Group One Trading first reported a position in 4D Molecular Therapeutics in Q4 2021 and held it in 8 quarters.
  • Group One Trading's 4D Molecular Therapeutics position peaked at $74.8K in Q4 2023.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.